Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...

Medically reviewed by Lindsay Cook, PharmD Ubrelvy (ubrogepant) and Nurtec (rimegepant) are prescription medications approved ...

Buy low, sell high. That has been a good strategy for investors for a long time. However, finding great stocks to buy under ...

The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it acquired paid kickbacks so that physicians would prescribe a specific migraine drug to patients.

Pfizer will pay $59.7 million to resolve charges that a company it acquired defrauded Medicare and other healthcare programs by paying kickbacks so doctors would prescribe the migraine drug Nurtec ODT ...

Pfizer reported strong 2024 profits Wednesday on the same day the Connecticut Attorney General’s office released a statement saying his office and 37 other states, including Puerto Rico, had settled ...

Florida's Medicaid Fraud Control Unit secured the win through a multistate action. "Actions, like those alleged here, must be ...

The Department of Justice (DoJ) claims that Biohaven – before being acquired by Pfizer – paid "improper remuneration" to some Nurtec ODT (rimegepant) prescribers in the form of speaker fees ...

Pfizer's earlier buy-in only gave it ex-US rights to rimegepant, already approved and on sale in the US as Nurtec ODT, so taking control of the entire company will give it full ownership of the ...

Pfizer paid $11.6bn to buy Biohaven, largely on the financial performance of Nurtec ODT. The drug went on to generate global sales of $928m in sales in 2023. Known as Vydura in Europe, Nurtec ODT ...

30, 2022, Biohaven Pharmaceuticals violated the federal False Claims Act by providing speaker honoraria and meals at high-end restaurants to doctors, to induce them to prescribe Nurtec more often.

Nurtec ODT, also known as Rimegepant, was approved for treating acute migraine in February 2020 and its approval was extended to preventing episodic migraine in June 2021. The drug was promoted by ...